What the FDA labels say about taking them together
Celecoxib and naproxen
Celecoxib's FDA label of November 22, 2024 names naproxen in its warnings and precautions section; naproxen's label does not name celecoxib itself but warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)). The celecoxib label: “A randomized controlled trial entitled the Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen Or Naproxen (PRECISION) was conducted to assess the relative cardiovascular thrombotic risk of a …”
Check it at the source: the celecoxib FDA label on DailyMed (effective November 22, 2024, Viatris Specialty LLC); the naproxen FDA label on DailyMed (effective March 12, 2026, Bayer HealthCare LLC.).
What does the celecoxib label say about naproxen?
Celecoxib label, warnings and precautionsA randomized controlled trial entitled the Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen Or Naproxen (PRECISION) was conducted to assess the relative cardiovascular thrombotic risk of a COX-2 inhibitor, celecoxib, compared to the non-selective NSAIDs naproxen and ibuprofen.
Source: FDA drug label (CELEBREX), NDA020998 (Upjohn), as published by Viatris Specialty LLC, effective November 22, 2024 (SPL set 2d6675e4-5859-4be2-8037-a20ce9f707aa), via openFDA; the full label on DailyMed
What does the naproxen label say about celecoxib?
Naproxen's label does not name celecoxib itself; it warns about its class (NSAIDs (nonsteroidal anti-inflammatory drugs)):
Naproxen label, boxed warningGastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
Naproxen label, boxed warningThis risk may occur early in treatment and may increase with duration of use ( 5.1 ) NAPRELAN® is contraindicated in the setting of coronary artery bypass graft (CABG) surgery ( 4 , 5.1 ) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
Source: FDA drug label (Aleve Caplets), Bayer HealthCare LLC., effective March 12, 2026 (SPL set 02941928-128a-2c88-e063-6294a90ac6ba), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Celecoxib | Naproxen | |
|---|---|---|
| Labeled for | Osteoarthritis, Rheumatoid arthritis, Pain, Migraine | Fever, Rheumatoid arthritis, Osteoarthritis, Gout, Pain, Cough and cold |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.0762 per capsule 200 mg capsule | $0.0565 per tablet 500 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once